Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Serina Therapeutics Inc (SER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SER (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.48% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.50M USD | Price to earnings Ratio 1.83 | 1Y Target Price 11 |
Price to earnings Ratio 1.83 | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 3.81 - 11.56 | Updated Date 06/30/2025 |
52 Weeks Range 3.81 - 11.56 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.38 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -37468.63% |
Management Effectiveness
Return on Assets (TTM) -135.82% | Return on Equity (TTM) -485.36% |
Valuation
Trailing PE 1.83 | Forward PE - | Enterprise Value 57458740 | Price to Sales(TTM) 1205.86 |
Enterprise Value 57458740 | Price to Sales(TTM) 1205.86 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 37.36 | Shares Outstanding 9967380 | Shares Floating 2792960 |
Shares Outstanding 9967380 | Shares Floating 2792960 | ||
Percent Insiders 64.23 | Percent Institutions 3.37 |
Analyst Ratings
Rating 1 | Target Price 11 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Serina Therapeutics Inc
Company Overview
History and Background
Serina Therapeutics Inc. is a preclinical stage biopharmaceutical company focusing on developing therapeutics based on its proprietary POZ Platform technology. Founded to address limitations of traditional drug delivery, the company aims to improve drug efficacy and safety.
Core Business Areas
- POZ Platform Technology: Serina's core business revolves around its POZ Platform, a technology designed to create drug conjugates with improved pharmacokinetic and pharmacodynamic properties. This platform forms the basis for their drug development pipeline.
Leadership and Structure
The leadership team includes individuals with expertise in drug development, business development, and finance. The company structure is typical of a small, preclinical stage biotech company, with a focus on research and development.
Top Products and Market Share
Key Offerings
- ST-2462: A POZ-conjugated formulation of topotecan (a chemotherapeutic agent) designed to improve the therapeutic index in treating solid tumors. Market share data is not available, as the product is still in preclinical development. Competitors include traditional topotecan formulations and other chemotherapeutic agents from companies like GlaxoSmithKline and Pfizer. Revenue not available as product is in clinical trials.
- ST-2460: A POZ-conjugated formulation of gemcitabine (a chemotherapeutic agent) designed to improve the therapeutic index in treating solid tumors. Market share data is not available, as the product is still in preclinical development. Competitors include traditional gemcitabine formulations and other chemotherapeutic agents from companies like Eli Lilly and Company. Revenue not available as product is in clinical trials.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. There is a strong demand for innovative drug delivery technologies to improve the efficacy and safety of existing and novel therapeutics.
Positioning
Serina Therapeutics is positioned as an innovator in the drug delivery space, specifically targeting improved drug conjugates using its POZ Platform. Its competitive advantage lies in its proprietary technology and its potential to enhance the performance of existing drugs.
Total Addressable Market (TAM)
The TAM for improved drug delivery technologies in oncology is substantial, estimated to be in the billions of dollars. Serina is positioned to capture a portion of this market through successful development and commercialization of its POZ Platform-based drugs.
Upturn SWOT Analysis
Strengths
- Proprietary POZ Platform technology
- Potential for improved drug efficacy and safety
- Focus on addressing limitations of existing drugs
Weaknesses
- Preclinical stage of development
- High reliance on successful clinical trials
- Limited financial resources
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of POZ Platform to other therapeutic areas
- Potential for orphan drug designations
Threats
- Clinical trial failures
- Competition from other drug delivery technologies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- LLY
- PFE
- GSK
Competitive Landscape
Serina's competitive advantage lies in its POZ Platform technology, which aims to improve drug delivery compared to traditional methods. However, it faces competition from established pharmaceutical companies with broader product portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development progress rather than revenue generation.
Future Projections: Future growth is contingent upon successful clinical trials, regulatory approvals, and commercialization of its POZ Platform-based drugs. Analyst estimates are unavailable.
Recent Initiatives: Recent initiatives include advancing lead drug candidates (ST-2462 and ST-2460) through preclinical and clinical studies.
Summary
Serina Therapeutics is a preclinical stage biopharmaceutical company with a promising drug delivery platform. Its future success hinges on positive clinical trial outcomes and securing partnerships. The company faces challenges typical of early-stage biotech firms, including funding and regulatory hurdles, however it has a unique platform with potential for improved therapeutics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (where available)
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biopharmaceutical industry is inherently risky, and investment decisions should be made after thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Serina Therapeutics Inc
Exchange NYSE MKT | Headquaters Huntsville, AL, United States | ||
IPO Launch date 2018-11-29 | CEO & Director Mr. Steven A. Ledger | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://serinatherapeutics.com |
Full time employees 12 | Website https://serinatherapeutics.com | ||
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.